Pershing Square Activist Presentation Deck slide image

Pershing Square Activist Presentation Deck

Pershing Square's Research ▸ At the time of Pershing Square's investment in Valeant, Pershing Square was aware that Valeant had a Specialty Pharmacy strategy ► We believed this strategy was a small component of Valeant's business ▸ By mid-2015, we became aware that Philidor was becoming a more significant part of Valeant's business and in July we conducted due diligence on Philidor and the specialty pharmacy channel ► Our due diligence confirmed that specialty pharmacies offer many benefits to doctors, patients, and manufacturers and were playing an increasingly important role in the distribution of prescription drugs ► We believed Philidor's business practices were similar to other specialty pharmacies ► We contacted Philidor and asked if the company was owned by Valeant; we were told "No." ► Until last week, Pershing Square did not know that Valeant had acquired an undisclosed purchase option in December 2014 25
View entire presentation